drugset
drugset / Trial / NCT05361174

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

NCT05361174 ↗

Phase 1/2 Recruiting 53 enrolled Iovance Biotherapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

Timeline

Start
2022-07-20
Primary completion
2027-09
Completion
2029-09

Drugs

EvaluationDrugModalityDoseRoute
Subject IOV-4001 Cell therapy — —

Indications

metastatic melanoma non-small cell lung carcinoma